Skip to main content
PMC home page
Gut logoLink to Gut
. 1999 Sep;45(3):435–441. doi: 10.1136/gut.45.3.435

Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort

M Lenzi 1, S Bellentani 1, G Saccoccio 1, P Muratori 1, F Masutti 1, L Muratori 1, F Cassani 1, F Bianchi 1, C Tiribelli 1
PMCID: PMC1727651  PMID: 10446115

Abstract

BACKGROUND—Several retrospective and prospective studies report an increased prevalence of non-organ-specific autoantibodies (NOSAs) in patients with hepatitis C virus (HCV) related chronic liver disease (CLD). Some of the data so far available are controversial and the true prevalence of NOSAs in the general population is still not known.
AIM—To explore the prevalence of NOSAs, their relation to different HCV genotypes, and the presence and severity of CLD in the general population of Northern Italy.
PATIENTS—All 226 anti-HCV positive and 87 hepatitis B surface antigen (HBsAg) positive patients of the Dionysos cohort study were analysed and compared with sex and age matched cases (226) negative for both anti-HCV antibody and HBsAg selected from the same cohort.
METHODS—Sera tested for the presence of NOSAs (anti-nuclear antibody (ANA), anti-smooth muscle antibody (SMA), and anti-liver/kidney microsomes type 1 antibody (LKM1)) were screened by indirect immunofluorescence at a 1:40 serum dilution. HCV RNA and HCV genotypes were also determined by nested polymerase chain reaction (PCR) of the 5' non-coding region and by PCR amplification of the core region with type specific primers.
RESULTS—The overall prevalence of NOSA reactivity was significantly higher in anti-HCV positive subjects than in both normal and pathological controls (25% v 6% and 7% respectively, p<0.05). ANA, SMA, and LKM1 occurred in 16, 10, and 1.3% of cases respectively. No specific association between NOSAs and a specific HCV genotype was found. NOSAs were found more often associated with more than one genotype (35.7%) and with untypable genotypes (34.6%), although the association was not statistically significant. NOSAs were associated with HCV RNA and CLD but not with the presence of cirrhosis and/or hepatocellular carcinoma. On univariate analysis, NOSA reactivity was independently associated with abnormal alanine aminotransferase (p<0.01) and γ-glutamyltranspeptidase levels (p<0.05). The risk for the presence of NOSAs was 5.1 times higher in anti-HCV subjects than in controls.
CONCLUSIONS—In the general population the prevalence of NOSAs is higher in anti-HCV positive subjects than in normal or disease controls. Moreover NOSAs are associated with CLD and with a more active disease in terms of alanine aminotransferase activity.


Keywords: non-organ-specific autoantibodies; hepatitis C virus genotypes; chronic liver disease; cohort study; prevalence

Full Text

The Full Text of this article is available as a PDF (103.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abuaf N., Lunel F., Giral P., Borotto E., Laperche S., Poupon R., Opolon P., Huraux J. M., Homberg J. C. Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol. 1993 Jul;18(3):359–364. doi: 10.1016/s0168-8278(05)80281-8. [DOI] [PubMed] [Google Scholar]
  2. Adinolfi L. E., Utili R., Attanasio V., Zampino R., Ragone E., Tripodi M. F., Ruggiero G. Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol. 1996 Jan;28(1):1–9. [PubMed] [Google Scholar]
  3. Agnello V., Chung R. T., Kaplan L. M. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992 Nov 19;327(21):1490–1495. doi: 10.1056/NEJM199211193272104. [DOI] [PubMed] [Google Scholar]
  4. Bellentani S., Tiribelli C., Saccoccio G., Sodde M., Fratti N., De Martin C., Cristianini G. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology. 1994 Dec;20(6):1442–1449. doi: 10.1002/hep.1840200611. [DOI] [PubMed] [Google Scholar]
  5. Block G., Hartman A. M., Dresser C. M., Carroll M. D., Gannon J., Gardner L. A data-based approach to diet questionnaire design and testing. Am J Epidemiol. 1986 Sep;124(3):453–469. doi: 10.1093/oxfordjournals.aje.a114416. [DOI] [PubMed] [Google Scholar]
  6. Bottazzo G. F., Florin-Christensen A., Fairfax A., Swana G., Doniach D., Groeschel-Stewart U. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol. 1976 May;29(5):403–410. doi: 10.1136/jcp.29.5.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cacoub P., Fabiani F. L., Musset L., Perrin M., Frangeul L., Leger J. M., Huraux J. M., Piette J. C., Godeau P. Mixed cryoglobulinemia and hepatitis C virus. Am J Med. 1994 Feb;96(2):124–132. doi: 10.1016/0002-9343(94)90132-5. [DOI] [PubMed] [Google Scholar]
  8. Cassani F., Bianchi F. B., Lenzi M., Volta U., Pisi E. Immunomorphological characterisation of antinuclear antibodies in chronic liver disease. J Clin Pathol. 1985 Jul;38(7):801–805. doi: 10.1136/jcp.38.7.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cassani F., Cataleta M., Valentini P., Muratori P., Giostra F., Francesconi R., Muratori L., Lenzi M., Bianchi G., Zauli D. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology. 1997 Sep;26(3):561–566. doi: 10.1002/hep.510260305. [DOI] [PubMed] [Google Scholar]
  10. Cassani F., Fusconi M., Bianchi F. B., Selleri L., Baffoni L., Lenzi M., Pisi E. Precipitating antibodies to rabbit thymus extractable antigens in chronic liver disease: relationship with anti-actin antibodies. Clin Exp Immunol. 1987 Jun;68(3):588–595. [PMC free article] [PubMed] [Google Scholar]
  11. Cassani F., Muratori L., Manotti P., Lenzi M., Fusconi M., Ballardini G., Selleri L., Volta U., Zauli D., Miniero R. Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: a reappraisal at the light of hepatitis C virus infection. Gut. 1992 Sep;33(9):1260–1263. doi: 10.1136/gut.33.9.1260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Clifford B. D., Donahue D., Smith L., Cable E., Luttig B., Manns M., Bonkovsky H. L. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995 Mar;21(3):613–619. [PubMed] [Google Scholar]
  13. Czaja A. J., Carpenter H. A., Santrach P. J., Moore S. B. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology. 1995 Jan;108(1):157–164. doi: 10.1016/0016-5085(95)90020-9. [DOI] [PubMed] [Google Scholar]
  14. Czaja A. J., Carpenter H. A., Santrach P. J., Moore S. B. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology. 1995 Jan;108(1):157–164. doi: 10.1016/0016-5085(95)90020-9. [DOI] [PubMed] [Google Scholar]
  15. Czaja A. J., Carpenter H. A., Santrach P. J., Moore S. B., Taswell H. F., Homburger H. A. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol. 1993 Jul;18(3):342–352. doi: 10.1016/s0168-8278(05)80279-x. [DOI] [PubMed] [Google Scholar]
  16. Czaja A. J., Manns M. P., Homburger H. A. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology. 1992 Oct;103(4):1290–1295. doi: 10.1016/0016-5085(92)91518-9. [DOI] [PubMed] [Google Scholar]
  17. Ferri C., Greco F., Longombardo G., Palla P., Moretti A., Marzo E., Fosella P. V., Pasero G., Bombardieri S. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum. 1991 Dec;34(12):1606–1610. doi: 10.1002/art.1780341221. [DOI] [PubMed] [Google Scholar]
  18. Fried M. W., Draguesku J. O., Shindo M., Simpson L. H., Banks S. M., Hoofnagle J. H., Di Bisceglie A. M. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci. 1993 Apr;38(4):631–636. doi: 10.1007/BF01316792. [DOI] [PubMed] [Google Scholar]
  19. Haddad J., Deny P., Munz-Gotheil C., Ambrosini J. C., Trinchet J. C., Pateron D., Mal F., Callard P., Beaugrand M. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet. 1992 Feb 8;339(8789):321–323. doi: 10.1016/0140-6736(92)91645-O. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Holborow E. J., Hemsted E. H., Mead S. V. Smooth muscle autoantibodies in infectious mononucleosis. Br Med J. 1973 Aug 11;3(5875):323–325. doi: 10.1136/bmj.3.5875.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Johnson P. J., McFarlane I. G. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993 Oct;18(4):998–1005. doi: 10.1002/hep.1840180435. [DOI] [PubMed] [Google Scholar]
  22. Johnson R. J., Gretch D. R., Yamabe H., Hart J., Bacchi C. E., Hartwell P., Couser W. G., Corey L., Wener M. H., Alpers C. E. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993 Feb 18;328(7):465–470. doi: 10.1056/NEJM199302183280703. [DOI] [PubMed] [Google Scholar]
  23. Lenzi M., Johnson P. J., McFarlane I. G., Ballardini G., Smith H. M., McFarlane B. M., Bridger C., Vergani D., Bianchi F. B., Williams R. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet. 1991 Aug 3;338(8762):277–280. doi: 10.1016/0140-6736(91)90418-o. [DOI] [PubMed] [Google Scholar]
  24. Lunel F., Abuaf N., Frangeul L., Grippon P., Perrin M., Le Coz Y., Valla D., Borotto E., Yamamoto A. M., Huraux J. M. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology. 1992 Sep;16(3):630–636. doi: 10.1002/hep.1840160304. [DOI] [PubMed] [Google Scholar]
  25. Lunel F., Musset L., Cacoub P., Frangeul L., Cresta P., Perrin M., Grippon P., Hoang C., Valla D., Piette J. C. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology. 1994 May;106(5):1291–1300. doi: 10.1016/0016-5085(94)90022-1. [DOI] [PubMed] [Google Scholar]
  26. Muratori L., Gibellini D., Lenzi M., Cataleta M., Muratori P., Morelli M. C., Bianchi F. B. Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood. 1996 Oct 1;88(7):2768–2774. [PubMed] [Google Scholar]
  27. Muratori L., Lenzi M., Cataleta M., Giostra F., Cassani F., Ballardini G., Zauli D., Bianchi F. B. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol. 1994 Aug;21(2):199–203. doi: 10.1016/s0168-8278(05)80395-2. [DOI] [PubMed] [Google Scholar]
  28. Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 1992 Mar;73(Pt 3):673–679. doi: 10.1099/0022-1317-73-3-673. [DOI] [PubMed] [Google Scholar]
  29. Papo T., Marcellin P., Bernuau J., Durand F., Poynard T., Benhamou J. P. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med. 1992 Jan 1;116(1):51–53. doi: 10.7326/0003-4819-116-1-51. [DOI] [PubMed] [Google Scholar]
  30. Pawlotsky J. M., Ben Yahia M., Andre C., Voisin M. C., Intrator L., Roudot-Thoraval F., Deforges L., Duvoux C., Zafrani E. S., Duval J. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994 Apr;19(4):841–848. [PubMed] [Google Scholar]
  31. Pedersen J. S., Toh B. H., Mackay I. R., Tait B. D., Gust I. D., Kastelan A., Hadzic N. Segregation of autoantibody to cytoskeletal filaments, actin and intermediate filaments with two types of chronic active hepatitis. Clin Exp Immunol. 1982 Jun;48(3):527–532. [PMC free article] [PubMed] [Google Scholar]
  32. Reddy K. R., Krawitt E. L., Homberg J. C., Jeffers L. J., de Medina M., Chastenay B., Poupon R., Opolon P., Beaugrand M., Abuaf N. Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat. 1995;2(4):175–179. doi: 10.1111/j.1365-2893.1995.tb00026.x. [DOI] [PubMed] [Google Scholar]
  33. Ruiz-Moreno M., Ruá M. J., Carreño V., Quiroga J. A., Manns M., Meyer zum Büschenfelde K. H. Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children. J Hepatol. 1991 Mar;12(2):265–266. doi: 10.1016/0168-8278(91)90953-9. [DOI] [PubMed] [Google Scholar]
  34. Tran A., Quaranta J. F., Benzaken S., Thiers V., Chau H. T., Hastier P., Regnier D., Dreyfus G., Pradier C., Sadoul J. L. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993 Aug;18(2):253–257. [PubMed] [Google Scholar]
  35. Wong V. S., Egner W., Elsey T., Brown D., Alexander G. J. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol. 1996 Apr;104(1):25–31. doi: 10.1046/j.1365-2249.1996.d01-639.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES